Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Association of Serum lncRNA CASC11 with Injury Severity and Inflammation in Spinal Cord Injury.

Created on 07 Jul 2026

Authors

Xueyan Hu, Lili Wang, Yuhui Ji, Jiayue Zhang, Liqi Zhao, Feng Wang, Na Yu

Published in

Journal of visualized experiments : JoVE. Issue 232. Jun 16, 2026. Epub Jun 16, 2026.

Abstract

Spinal cord injury (SCI) is a severe central nervous system trauma. This single-center, observational and in vitro study investigated the diagnostic potential of CASC11 and its possible regulatory mechanism in SCI using clinical serum samples and lipopolysaccharide-stimulated cell models. CASC11, miR-130b-5p, and SPP1 levels were measured by real-time quantitative polymerase chain reaction (RT-qPCR). Cellular functions and targeting relationships were assessed via cell counting kit-8 (CCK-8), flow cytometry, western blot, enzyme-linked immunosorbent assay (ELISA), dual-luciferase reporter, and RNA immunoprecipitation (RIP) assays. CASC11 was highly expressed in SCI and associated with inflammation as a potential diagnostic biomarker. In lipopolysaccharide (LPS)-treated PC-12 cells, silencing CASC11 alleviated suppressed cell activity, apoptosis, and inflammation, which was reversed by miR-130b-5p inhibitor. These findings suggest that CASC11 is associated with SCI severity, while in vitro data indicate its involvement in inflammatory and apoptotic responses through the CASC11/miR-130b-5p/SPP1 axis. This study is limited by its single-center design and lack of in vivo validation.

PMID:
42406829
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement